FDA Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anthrax Vaccines
Emergent BioSolutions Delivers Approximately 1 Million Doses of BioThrax Ahead of Schedule to U.S. Department of Health and Human Services for Strategic National Stockpile
March 15th, 2007
Emergent BioSolutions Inc. (NYSE: EBS) announced that yesterday it delivered just under one million doses of BioThrax(R) (Anthrax Vaccine Adsorbed), the only FDA licensed anthrax vaccine, to the Department of Health and Human Services (HHS) for placement into the nation's strategic national stockpile (SNS). This delivery represents revenue of approximately $22 million generated during 1Q 2007. These doses were provided to HHS ahead of schedule under a May 2006 modified contract that required the company to deliver five million doses to HHS before May 31, 2007. Since May 2005, the company has supplied 10 million doses of BioThrax to HHS for inclusion in the SNS. "I am...
Source: FDA Law Weekly (2007-03-15)
|
